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This editorial is an introduction to the special issue ‘Schizophrenia and Sleep Disorders’.
It provides a brief overview of the research field, discusses the four main studies of the special
issue, and gives some important directions for future research.
Schizophrenia is characterized by the so-called positive symptoms, negative symptoms,
and cognitive symptoms [1] (see Figure 1). Contrary to what might be thought, the positive symptoms
are not positive for the patient; rather, the name solely refers to symptoms that are “added to” or
visible in patients with schizophrenia, but not in healthy individuals. Here, for the typical patient with
schizophrenia, one can think of auditory-, visual-, olfactory-, tactile-, or gustatory- hallucinations and
delusions, etc. [2]. Examples of negative symptoms (symptoms that are visible in healthy individuals,
but not in patients with schizophrenia) are, for instance, the flat affect, inability to experience
pleasure, emotional withdrawal, active social avoidance, lack of motivation, etc. [3]. Problems in
executive functioning, including problems with working memory [4], focused and sustained attention,
and problem solving, deficits in response initiation and suppression, etc. [5], are examples of cognitive
symptoms. Schizophrenia is a severe psychiatric disorder and has a large impact on the patient’s life.
Most patients suffer from the disorder for a long time, even a lifetime, and the costs for society are
high [6]. The severity of the disorder manifests itself in a high suicide rate, with about 10% of the
patients suffering from schizophrenia committing suicide [5].
Schizophrenia is relatively common. Its worldwide prevalence is estimated to be around 0.5% [7],
and its occurrence appears to be related to genetics [8]. For instance, a number of common genetic
variants, rare copy-number variants, and ultra-rare gene-disrupting mutations have been found to
play a role in schizophrenia [9]. Less familiar to the general public is the fact that most patients with
schizophrenia also suffer from sleep problems [10] (see Figure 1). Common disturbances reported in
clinical studies are reduced sleep efficiency, reduced total sleep time, and increased sleep latency [11].
Even more surprisingly is the fact that those sleep disturbances in patients with schizophrenia are
frequently not accounted for in daily clinical practice [11].
The aim of this special issue will be to provide an overview of the specific sleep disturbances
experienced by patients with schizophrenia and the negative effects of those disturbances on cognition;
moreover, the different kinds and combinations of treatment techniques available to date will be
discussed, with a focus on the following question: How can one develop the best treatment for sleep
disorders in patients with schizophrenia, sufficiently taking into account the different stages of the
disorder and the individual differences between the patients?
The first study by Assimakopoulos and colleagues [12] in our special issue focuses on the topic
of genetic variations in patients suffering from schizophrenia and co-morbid sleep disorders. From
previous research, genetics is known to play an important role in schizophrenia, indicating that
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some individuals are genetically more at risk to develop schizophrenia later in life than others [8].
The study by Assimakopoulos et al. [12] is unique because it taps not only into genetics but also into
the co-morbid sleep disorders of patients with schizophrenia. In their study, the authors searched the
PubMed, ScienceDirect, and GoogleScholar databases and followed the guidelines of the Preferred
Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) protocol. In total, 11 eligible
studies were found. The results revealed that certain genetic variations were indeed found to be
associated with schizophrenia-related sleep disorders. For instance, antipsychotic-induced restless
legs syndrome was linked to polymorphisms located on the CLOCK, BTBD9, GNB3, and TH genes.
Moreover, clozapine-induced somnolence was correlated with polymorphisms of the HNMT gene.
In addition, insomnia was associated with variants of the MTNR1 gene. The authors conclude that
significant genetic associations exist between schizophrenia and co-morbid sleep disorders, implicating
the circadian system, dopamine and histamine metabolism, and signal transduction pathways [12].
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are the focus of the present special issue and are suggested to influence those symptoms.
The second article by Bosch and colleagues [13] focuses on the pharmacological treatment
of long-term patients with schizophrenia, which is still the cornerstone of disease management.
However, how pharmacological treatment affects sleep and whether gender differences exist remain
unclear, so these questions were the main issues that were investigated. To that end, the numbers of
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antipsychotics, sleep medications, antidepressants, and anxiolytics used by 46 long-term outpatients
with schizophrenia were analyzed. In addition, the scores of the patients on the Pittsburgh Sleep
Quality Index (PSQI) [14] and the Epworth Sleepiness Scale (ESS) [15] were analyzed. The results of
the study revealed a large individual variability; some patients received no psychiatric drugs at all
whereas other patients received up to eight different psychiatric medications at a time. Moreover,
the patients were found to have high scores on the PSQI, but not on the ESS. This means that although
the patients with schizophrenia report problems with sleep, they do not feel sleepy during the day.
A significant positive correlation between the use of antipsychotics and the ESS score, but not the
PSQI score, was found. The statistical analyses of the data revealed no gender differences in the
pharmacological treatment of long-term patients with schizophrenia. The authors conclude that a large
variability exists in the pharmacological treatment of such patients. Moreover, to date, not enough
attention has been paid to the treatment of schizophrenic patients’ sleep problems and to the gender
differences in the pharmacological treatment of those patients. Finally, the authors stress the point
that a need exists for more and larger replication studies in order to verify the present study findings
and in order to recommend any changes in the drug treatment of male and female patients with
long-term schizophrenia.
The third study by Stummer and colleagues [16] goes deeper into the pharmacological treatment
of sleep disorders in patients with schizophrenia. The authors conducted a literature search through
OVID and PubMed to find relevant publications on pharmacotherapy options to treat insomnia in
patients with schizophrenia. The results of that review show that only a few evidence-based options
are available to treat insomnia in patients with schizophrenia, including selecting a more sedating
second-generation antipsychotic, such as paliperidone, or adding melatonin or eszopiclone. However,
the authors stress the important need for further randomized controlled trials to verify these findings.
The fourth study by Van den Noort and colleagues [17] taps the issue that, in addition to Western
medicine, the use of other methods, such as acupuncture, to treat the positive, negative, and cognitive
symptoms of patients with schizophrenia is on the rise. A systematic review that included all studies
involving the use of standard acupuncture in the treatment of patients with schizophrenia was
conducted. The authors searched the Medline, ScienceDirect, Cochrane Library, Scopus, and ERIC
databases. Moreover, the study was conducted in accordance with the PRISMA protocol. Twenty-six
studies fulfilled all selection criteria. In total, 1181 patients with schizophrenia were treated with
acupuncture. The results showed that most studies found only small beneficial effects of acupuncture in
the treatment of the positive, negative, and cognitive symptoms. However, larger beneficial effects were
found regarding the treatment of the accompanying sleep disorders in patients with schizophrenia,
leading the authors to propose the “Acupuncture–Dopamine–Sleep” (ADS) hypothesis. It states
that “acupuncture is able to affect the disturbed and hyperactive dopamine system in patients with
schizophrenia, bringing it back into balance, and as a result, the patients start to feel and function
better, without necessarily getting rid of all their clinical symptoms” [17]. Finally, the authors stress the
point that the results found in their review study need to be confirmed by future large, randomized,
controlled trials that to date are, unfortunately, to a large extent missing.
In future research, if a better understanding of genetic variations in patients with schizophrenia
and co-morbid sleep disorders is to be achieved, more studies on the circadian system, dopamine and
histamine metabolism, and signal transduction pathways in such patients are required. Moreover,
future pharmacological studies should focus more on the patients’ sleep problems. In addition,
individual and gender differences need to be taken into account if a more optimal pharmacological
treatment is to be found. With respect to the usefulness of acupuncture as an add-on treatment
for patients with schizophrenia and co-morbid sleep disorders, the ADS hypothesis seems to be
a promising working hypothesis to focus on in future acupuncture research. (For an overview of the
main topics for future research, see Figure 2.)
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Taking all of the above together, one can conclude that to date, an optimal treatment for patients
with schizophrenia and co-morbid sleep disorders may still be a long way off. Much research remains to
be done before the relation between genetics and clinical symptoms is fully understood and, as a result,
before good individual-based (pharmacological) treatments can be offered. One must remain skeptical
about, and critically assess, the limited treatment successes obtained so far. A hope of the authors
is that i portant progress will soon be made in the treatment of patients with schizophrenia and
co-morbid sleep disorders so that the great suffering of those patients and their families and friends
can be reduced. The authors hope that the subjects of the present special issue will stimulate discussion
and encourage research on the way to achieve this goal.
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